Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393106 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01393106 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 25 participants.
The verdict
NCT01393106, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of idelalisib in participants with relapsed of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall response rate. Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg twice daily. Treatment with idelalisib will continue until tumor progression or unacceptable toxicity.
Interventions
- DRUG Idelalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393106
The ClinicalTrials.gov registry entry for NCT01393106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Idelalisib is the first listed.
NCT01393106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01393106 about?
NCT01393106 is a clinical study titled "Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma". This study will evaluate the efficacy and safety of idelalisib in participants with relapsed of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall response rate. Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg twice da...
What is the current status of trial NCT01393106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-09. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01393106?
The interventions under investigation include: Idelalisib (DRUG).
Who is sponsoring clinical trial NCT01393106?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.